[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562272":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":38,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":44,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":54,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Diagnosis of pancreatic cancer",null,"Patients diagnosis of pancreatic cancer require immunotherapy or combination immunotherapy after evaluation according to clinical guidelines",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Jiajia Hu","CONTACT","13524945287","jiajiahu@shsmu.edu.cn",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine","RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":28,"coordinates":29},"Point",[30,31],121.45806,31.22222,{"lat":31,"lon":30},[34],{"name":35,"role":15,"phone":36,"phoneExt":10,"email":37},"Chenlei Wen","13761638756","wcl12161@rjh.com.cn",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Hu Jiajia","Deputy director","100562272","the-value-of-68ga-grazytracer-pet-in-monitoring-responses-to-immunotherapy-of-pancreatic-cancer-100562272",false,"NCT06601010","The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.","Inclusion Criteria:\n\n1. Pathological diagnosis of pancreatic cancer requiring combination immunotherapy after evaluation according to clinical guidelines\n2. Signed and dated informed consent form\n3. Commitment to comply with research procedures and co-operation in the implementation of the full research process 4 .aged 18-75 years old 5 .The patient is in good general condition with an expected survival of \\> 6 months\n\nExclusion Criteria:\n\n1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.\n2. Intestinal perforation, complete intestinal obstruction\n3. Pregnant women and women who may be pregnant, women who are breastfeeding.\n4. Non-compliant person","ALL","18 Years","75 Years",{"count":52,"type":53},30,"ESTIMATED","1 Year","OBSERVATIONAL","This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.",[58],"Pancreatic Cancer",[60,61,62],"68Ga-grazytracer PET\u002FCT","Pancreatic cancer","Immunotherapy","2024-12-09",{"date":65,"type":66},"2024-12-11","ACTUAL",{"date":68,"type":66},"2024-09-24",{"date":70,"type":53},"2027-08-31",{"name":5,"class":6},1]